Brief Title: SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

PRIMARY OUTCOMES

Primary Outcome 1 - Measure: Proportion of patients Eligible for CTE versus Actual CTE

Primary Outcome 1 - Timeframe: Through study completion

CONDITION

• Cancer
• Metastatic
• Cancer
• Cancer of Pancreas
• Cancer of Liver
• Cancer of Stomach
• Cancer Liver
• Cancer of Rectum
• Cancer of Kidney
• Cancer of Esophagus
• Cancer of Cervix
• Cancer of Colon
• Cancer of Larynx
• Cancer
• Lung
• Cancer
• Breast
• Cancer
• Advanced
• Cancer Prostate
• Cancer of Neck
• Cancer of Skin
• Neuroendocrine Tumors
• Carcinoma
• Mismatch Repair Deficiency
• BRCA Gene Rearrangement
• Non Hodgkin Lymphoma
• Leukemia
• Non Small Cell Lung Cancer
• Cholangiocarcinoma
• Glioblastoma
• Central Nervous System Tumor
• Melanoma
• Urothelial Carcinoma
• Bladder Cancer
• Ovarian Cancer
• Endometrial Cancer
• Testicular Cancer
• Breast Cancer
• COVID
• Myelofibrosis
• Myeloproliferative Neoplasm
• Myeloproliferative Disorders
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Myelodysplastic Syndromes

ELIGIBILITY

Inclusion Criteria:
* Pts with solid and hematological malignancies;

- * Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2, HER2/Neu, Tumor mutational burden/load (TMB), ABL1, ACVR1B, AKT1, AKT2, AKT3, ALK, APC, AR, ATM, ATRX, AURKA, AURKB, BAP1, BCL2, BCL6, BRAF, BRCA1, BRCA2, BTK, CCND1, CCND2, CCND3, CDK4, CDK6, CDKN1A/B, CEBPA, CHEK1, CHEK2, CSF1R, CTNNB1, DAXX, DDR1/2, DNMT3A, EGFR, ERBB2, ERBB3, ERBB4, ERCC4, ER, ESR1, FANCA, FAS, FBXW7, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GATA3, GATA6, GNAS, HDAC1, HGF, HRAS, IDH1, IDH2, IGF1R, JAK1, JAK2, JAK3, KDR (VEGFR2), KIT, KRAS, MAP2K2 (MEK2), MAP3K1, MCL1, MDM2, MDM4, MEN1, MET, MSH2, MSH3, MSH6, MTOR, MUTYH, MYC, MYCL (MYCL1), NF1, NF2, NOTCH1, NPM1, NRAS, NTRK1, NTRK2, NTRK3, PALB2, PARP1, PARP2, PARP3, PBRM1, PDCD1 (PD1), PDCD1LG2 (PD-L2), PDGFRA, PDGFRB, PIK3C, PMS2, POLD1, POLE, PRDM1, PTCH1, PTEN, RAF1, RB1, RET, RICTOR, ROS1, RPTOR, SDHA/B/C, SMAD, SMARC, SMO, STK11, TGFBR2, TP53, TSC1, TSC2, VEGFA, VHL, WT1, ZNF217, ZNF703, CEACAM, NRG1, among others.
These biomarkers should be determined by local laboratory, external vendor, or next generation sequencing platform
* Decision to consider clinical trial pre-screening enrollment (CTE) by primary provider and/or patient
Exclusion Criteria:
* ECOG PS > 2;

- * Abnormal organ function;

- * Hospice enrollment

Gender: All

Minimum Age: N/A

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: Selin Kurnaz, PhD

Role: Principal Investigator

Affiliation: Massive Bio, Inc.

Overall Contact

Name: Fiona Evans, MS, Diego Barrenechea, MD

Phone: +1 (844) 627-7246, + 1 (646) 586-2753

Email: [email protected], [email protected]

LOCATION